10/20/2021

Gilead's Sacituzumab Govitecan-hziy (TRODELVY) is Now a Preferred Treatment Option, as Early as 2L For mTNBC

SACITUZUMAB GOVITECAN-HZIY (TRODELVY) IS NOW A PREFERRED TREATMENT OPTION, AS EARLY AS 2L FOR mTNBC

NCCN GUIDELINES®: Sacituzumab govitecan-hziy (TRODELVY) is recommended as a preferred treatment option* for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.1,2

*Category 2A.

 
Important Safety Information  |  Full Prescribing Information

TRODELVY® (sacituzumab govitecan-hziy) is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.

Please click to see full Prescribing Information, including BOXED WARNING for Neutropenia and Diarrhea.

 
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
 
2L=second line; Category 2A=based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate2; NCCN=National Comprehensive Cancer Network.